Elizaveta Golubeva, Aleksandra Ochneva, Angelina Zeltser, Denis Andreyuk, G. P. Kostyuk, A M Reznik, Svetlana Askerko, Daria Isaeva, Julia Fedotova
Post-traumatic stress disorder (PTSD) is a complex psychiatric condition arising from exposure to severe trauma, characterized by intrusive memories, avoidance, negative alterations in cognition and mood, and hyperarousal.Despite advances in understanding its neurobiology, effective pharmacotherapies remain limited.Dysregulation of the hypothalamic-pituitary-adrenal axis is a hallmark of PTSD, though findings on systemic cortisol levels remain inconsistentsuggesting that local, tissue-specific glucocorticoid metabolism may play a particularly relevant role beyond circulating hormone concentrations.The enzymes 11-hydroxysteroid dehydrogenases (11-HSDs), particularly 11-HSD1, regulate intracellular glucocorticoid availability in the brain and periphery and may contribute to region-specific modulation of stress-related neurocircuitry.This focused mini-review synthesizes available preclinical and clinical evidence on the involvement of 11-HSDs in PTSD.Preclinical studies consistently implicate 11-HSD1 in fear memory processing and stress adaptation, while emerging human data suggest a more complex and context-dependent role.Notably, recent neuroimaging findings indicate that higher brain 11-HSD1 availability may be associated with lower severity of specific symptom domains, raising the possibility of adaptive or compensatory mechanisms in chronic PTSD.Although the current clinical evidence base remains limited, these observations support the view that local glucocorticoid metabolism represents a biologically meaningful dimension of PTSD pathophysiology.Further integrative studies combining neuroimaging, molecular, and clinical approaches are needed to better define the contribution of 11-HSD enzymes to PTSD pathophysiology and to evaluate their potential as candidate molecular pathways for future research.